Ciprofloxacin pills 500mg, 10pcs

Composition

Per tablet:

Active ingredient:

ciprofloxacin hydrochloride-582.20 mg (in terms of ciprofloxacin-500.00 mg);

Tablet Core Excipients:

corn starch-7.20 mg;

partially pregelatinized corn starch (Starch 1500) – 60.00 mg;

microcrystalline cellulose-86.20 mg;

crospovidone (collidone CL) – 15.40 mg;

magnesium stearate-7.60 mg;

lactose monohydrate-26.60 m;

talc-14.80 mg.

Excipients of the film shell:

hypromellose – 11.56 mg;

polyethylene glycol 6000-4.88 mg;

titanium dioxide-1.78 mg;

polysorbate 80-1.78

mgPharmacological action

Broad-spectrum antimicrobial agent of the fluoroquinolone group. It has a bactericidal effect. Inhibits DNA gyrase and inhibits bacterial DNA synthesis.

Highly active against most gram-negative bacteria: Pseudomonas aeruginosa, Haemophilus influenzae, Escherichia coli, Shigella spp., Salmonella spp., Neisseria meningitidis, Neisseria gonorrhoeae.

Active against Staphylococcus spp. (including strains that produce and do not produce penicillinase, methicillin-resistant strains), some strains of Enterococcus spp., Campylobacter spp., Legionella spp., Mycoplasma spp., Chlamydia spp., Mycobacterium spp.

Ciprofloxacin is active against beta-lactamase-producing bacteria.

Ureaplasma urealyticum, Clostridium difficile, and Nocardia asteroides are resistant to ciprofloxacin. The effect on Treponema pallidum has not been sufficiently studied.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to ciprofloxacin, including diseases of the respiratory tract, abdominal cavity and pelvic organs, bones, joints, skin; septicemia; severe infections of ENT organs. Treatment of postoperative infections. Prevention and treatment of infections in patients with reduced immunity.

For topical use: acute and subacute conjunctivitis, blepharoconjunctivitis, blepharitis, bacterial corneal ulcers, keratitis, keratoconjunctivitis, chronic dacryocystitis, meibomitis. Infectious eye damage after injury or foreign body contact. Preoperative prevention in ophthalmic surgery.

Recommendations for use

Individual approach. Inside-250-750 mg 2 times/day. The duration of treatment is from 7-10 days to 4 weeks.

For intravenous use, a single dose is 200-400 mg, the frequency of use is 2 times/day; the duration of treatment is 1-2 weeks, if necessary, and more. It can be administered intravenously in a jet, but more preferably drip use for 30 minutes.

When applied topically,1-2 drops are instilled into the lower conjunctival sac of the affected eye every 1-4 hours. After the condition improves, the intervals between instillations can be increased.

The maximum daily dose for adults when taken orally is 1.5 g.

Contraindications

Pregnancy, lactation (breastfeeding), children and adolescents under 18 years of age, hypersensitivity to ciprofloxacin and other quinolone drugs.

Side effects

From the digestive system:  nausea, vomiting, diarrhea, abdominal pain, increased activity of hepatic transaminases, ALP, LDH, bilirubin, pseudomembranous colitis.

From the central nervous system:  headache, dizziness, fatigue, sleep disorders, nightmares, hallucinations, fainting spells, visual disturbances.

From the urinary system:  crystalluria, glomerulonephritis, dysuria, polyuria, albuminuria, hematuria, transient increase in serum creatinine.

From the hematopoietic system:  eosinophilia, leukopenia, neutropenia, changes in the number of platelets.

From the cardiovascular system:  tachycardia, cardiac arrhythmias, hypotension.

Allergic reactions:  pruritus, urticaria, angioedema, Stevens-Johnson syndrome, arthralgia.

Adverse reactions associated with chemotherapeutic action:  candidiasis.

Local reactions:  soreness, phlebitis (with intravenous use). When using eye drops, in some cases, mild soreness and hyperemia of the conjunctiva are possible.

Other services:  vasculitis.

Interaction

When ciprofloxacin is co-administered with didanosine, the absorption of ciprofloxacin decreases due to the formation of ciprofloxacin complexes with aluminum and magnesium buffers contained in didanosine.

When used concomitantly with warfarin, the risk of bleeding increases.

With the simultaneous use of ciprofloxacin and theophylline, it is possible to increase the concentration of theophylline in blood plasma, increase T_1/2of theophylline, which leads to an increased risk of toxic effects associated with theophylline.

Simultaneous use of antacids, as well as drugs containing aluminum, zinc, iron or magnesium ions, may cause a decrease in the absorption of ciprofloxacin, so the interval between the appointment of these drugs should be at least 4 hours.

Special instructions

In patients with impaired renal function, dosage adjustment is required. It is used with caution in elderly patients, with atherosclerosis of the cerebral vessels, cerebrovascular disorders, epilepsy, convulsive syndrome of unclear etiology.

Patients should receive sufficient fluids during treatment.

In case of persistent diarrhea, ciprofloxacin should be discontinued.

Simultaneous intravenous use of ciprofloxacin and barbiturates requires monitoring of heart rate, blood pressure, and ECG. During treatment, it is necessary to control the concentration of urea, creatinine, and hepatic transaminases in the blood.

During the treatment period, the reactivity may decrease (especially when used simultaneously with alcohol).

Ciprofloxacin should not be administered subconjunctivally or directly into the anterior chamber of the eye.

Active ingredient

Ciprofloxacin

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Otitis Media, Prostatitis, Bronchitis, Intestinal Infections, Skin Infections, Infectious Diseases, Pneumonia, Sinusitis, Urinary Tract Infections, Osteomyelitis, Salmonellosis, Diarrhea, Sinusitis, Respiratory Tract infections